These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12611785)

  • 1. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study.
    Scott J; Palmer S; Paykel E; Teasdale J; Hayhurst H
    Br J Psychiatry; 2003 Mar; 182():221-7. PubMed ID: 12611785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: an economic evaluation based on a randomized trial.
    Asante M; Lord J; Mendall M; Northfield T
    Eur J Gastroenterol Hepatol; 1999 Aug; 11(8):851-6. PubMed ID: 10514116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.
    Petrou S; Bischof M; Bennett C; Elbourne D; Field D; McNally H
    Pediatrics; 2006 May; 117(5):1640-9. PubMed ID: 16651318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of relapse in residual depression by cognitive therapy: a controlled trial.
    Paykel ES; Scott J; Teasdale JD; Johnson AL; Garland A; Moore R; Jenaway A; Cornwall PL; Hayhurst H; Abbott R; Pope M
    Arch Gen Psychiatry; 1999 Sep; 56(9):829-35. PubMed ID: 12884889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents.
    Sculpher M; Thompson E; Brown J; Garry R
    BJOG; 2000 Mar; 107(3):340-6. PubMed ID: 10740330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care: economic analysis.
    Miller P; Chilvers C; Dewey M; Fielding K; Gretton V; Palmer B; Weller D; Churchill R; Williams I; Bedi N; Duggan C; Lee A; Harrison G
    Int J Technol Assess Health Care; 2003; 19(1):80-90. PubMed ID: 12701941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Cognitive Behavioral Therapy for Depressed Youth Declining Antidepressants.
    Dickerson JF; Lynch FL; Leo MC; DeBar LL; Pearson J; Clarke GN
    Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29351965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness in the management of patients with oesophageal cancer.
    Farndon MA; Wayman J; Clague MB; Griffin SM
    Br J Surg; 1998 Oct; 85(10):1394-8. PubMed ID: 9782023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of accuracy and cost effectiveness of clinical criteria and BUA for referral for BMD assessment by DXA in osteoporotic and osteopenic perimenopausal subjects.
    Langton CM; Langton DK; Beardsworth SA
    Technol Health Care; 1999; 7(5):319-30. PubMed ID: 10543417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
    Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
    Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study.
    Price D; Haughney J; Lloyd A; Hutchinson J; Plumb J
    Curr Med Res Opin; 2004 Oct; 20(10):1671-9. PubMed ID: 15462701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
    Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
    Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases.
    Durand-Zaleski I; Earlam S; Fordy C; Davies M; Allen-Mersh TG
    Cancer; 1998 Sep; 83(5):882-8. PubMed ID: 9731890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial cost of social exclusion: follow up study of antisocial children into adulthood.
    Scott S; Knapp M; Henderson J; Maughan B
    BMJ; 2001 Jul; 323(7306):191. PubMed ID: 11473907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.
    Beck EJ; Tolley K
    Int J STD AIDS; 1998 Sep; 9(9):512-7. PubMed ID: 9764934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supported self-help to prevent relapse or recurrence of depression: Who benefits most?
    Dijkstra-Kersten SM; Biesheuvel-Leliefeld KE; van der Wouden JC; van Schaik DJ; Bosmans JE; van Marwijk HW; van der Horst HE
    J Affect Disord; 2019 Oct; 257():180-186. PubMed ID: 31301621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.